Comparative Pharmacology
Head-to-head clinical analysis: PLENAXIS versus SPIRONOLACTONE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: PLENAXIS versus SPIRONOLACTONE.
PLENAXIS vs SPIRONOLACTONE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Selective androgen receptor modulator (SARM); binds to androgen receptors with high affinity, activating anabolic signaling pathways in muscle and bone with reduced androgenic effects on prostate and skin.
Competitive antagonist of mineralocorticoid receptors in the distal convoluted tubule, inhibiting sodium reabsorption and potassium excretion; also has antiandrogenic activity by inhibiting androgen biosynthesis and blocking androgen receptors.
Initial: 10 mg orally once daily, titrated to blood pressure and heart rate response; maintenance: 20-80 mg daily in 1-2 divided doses.
Oral: 25-200 mg daily in 1-2 divided doses for hypertension, heart failure, or cirrhosis with ascites. Maximum 400 mg/day.
None Documented
None Documented
Clinical Note
moderateSpironolactone + Digitoxin
"The therapeutic efficacy of Digitoxin can be decreased when used in combination with Spironolactone."
Clinical Note
moderateSpironolactone + Deslanoside
"The therapeutic efficacy of Deslanoside can be decreased when used in combination with Spironolactone."
Clinical Note
moderateSpironolactone + Acetyldigitoxin
"The therapeutic efficacy of Acetyldigitoxin can be decreased when used in combination with Spironolactone."
Clinical Note
moderateTerminal elimination half-life is approximately 24 hours in healthy adults; clinically significant accumulation occurs in renal impairment (CrCl <30 mL/min) with half-life prolonged to 40-60 hours.
Spironolactone: 1.4-2.5 hours; active metabolites: canrenone 16.5-22.5 hours, 7α-thiomethylspironolactone 10-15 hours. Clinical context: Metabolite half-lives determine dosing interval (once or twice daily).
Renal: 70% as unchanged drug; fecal: 10% as metabolites; biliary: 5% as unchanged drug and metabolites.
Renal: approximately 50% as metabolites (canrenone, 7α-thiomethylspironolactone) and unchanged drug; Biliary/Fecal: approximately 35% as metabolites; the remainder undergoes enterohepatic recirculation.
Category C
Category D/X
Aldosterone Antagonist
Aldosterone Antagonist
Spironolactone + Ouabain
"The therapeutic efficacy of Ouabain can be decreased when used in combination with Spironolactone."